You are here

Article Text

Article menu
Download PDFPDF
Letter
Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra
  1. Loes M Kuijk1,
  2. Anita M A P Govers1,
  3. Willem J D Hofhuis2,
  4. Joost Frenkel1
  1. 1
    Departments of General Pediatrics and Pediatric Immunology, Division of Pediatrics, University Medical Center, Utrecht, the Netherlands
  2. 2
    Department of Pediatrics, Catharina Hospital, Eindhoven, the Netherlands
  1. Dr J Frenkel, Department of General Pediatrics, University Medical Center, Lundlaan 6, 3584EA Utrecht, the Netherlands; j.frenkel{at}umcutrecht.nl

https://doi.org/10.1136/ard.2007.071498

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Familial Mediterranean fever (FMF) is an autoinflammatory disorder, characterized by periodic fever and serosal inflammation, often complicated by systemic amyloidosis. Maintenance treatment of FMF with colchicine can reduce disease activity and prevent amyloidosis. Some patients, however, fail colchicine therapy. Many reports have recently been published concerning the effective use of a recombinant IL-1 receptor antagonist, anakinra, in several closely related disorders.1–4 These results prompted us to use anakinra in a 14-year-old FMF patient who was unresponsive to colchicine therapy (2 mg/day). A diagnosis of FMF was confirmed by analysis of the MEFV gene (pM694V, M694I).

    The …

    View Full Text

    Footnotes

    • Funding: L M K is supported by a grant from the Wilhelmina Children’s Hospital Research Fund.